AKIGAI

Pre-clinical

Oslo, NorwayFounded 2020akigai.no

AKIGAI is a private, preclinical-stage biotech company founded in 2020 in Oslo, Norway, focused on developing disruptive drugs for neuropathic pain. The company's foundation is the serendipitous discovery and subsequent patenting of the use of EGFR inhibitors for neuropathic pain relief, supported by preclinical research and clinical observations in over 100 patients across 10 clinics. AKIGAI is pursuing a dual-path development strategy involving both tyrosine kinase inhibitors and monoclonal antibodies, and is actively seeking partners to advance its programs toward clinical validation and commercialization.

Founded

2020

Focus

Digital HealthAI / Machine Learning

AI Company Overview

Technology Platform

Repurposing and development of EGFR (Epidermal Growth Factor Receptor) inhibitors, a class of oncology drugs, for the novel application of treating neuropathic pain, supported by a patented use and strong clinical observations.

Opportunities

The massive unmet need in neuropathic pain (10% prevalence, poor current treatments) presents a multi-billion dollar market opportunity.

Repurposing established EGFR inhibitors could enable a faster and lower-risk development pathway.

Positive clinical data could lead to lucrative partnerships with large pharmaceutical companies seeking novel pain therapeutics.

Risk Factors

Major risks include the need to confirm striking observational data in rigorous controlled clinical trials, potential side effects from chronic EGFR inhibitor use in a non-cancer population, challenges in commercializing a potentially high-cost drug in a generic-dominated market, and dependence on securing significant funding or partnerships to advance development.

Competitive Landscape

AKIGAI faces competition from generic gabapentinoids/SNRIs and novel mechanism drugs from large pharma (e.g., Vertex). Its key differentiation lies in strong human proof-of-concept data (>100 patients), a novel non-CNS/non-addictive mechanism (EGFR inhibition), and patented use of an established drug class, offering a potentially faster path to an effective therapy.